Zhangzhou Pientzehuang Pharmaceutical Co Ltd
SSE:600436
Zhangzhou Pientzehuang Pharmaceutical Co Ltd
SSE:600436
Price:
159.89
CNY
-0.32%
Market Closed
Market Cap:
¥96.5B
Relative Value
The Relative Value of one
Zhangzhou Pientzehuang Pharmaceutical Co Ltd
stock under the Base Case scenario is
102.34
CNY.
Compared to the current market price of 159.89 CNY,
Zhangzhou Pientzehuang Pharmaceutical Co Ltd
is
Overvalued by 36%.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
Relative Value
Base Case
102.34
CNY
Overvaluation 36%
Multiples Across Competitors
Competitors Multiples
Zhangzhou Pientzehuang Pharmaceutical Co Ltd Competitors
Zhangzhou Pientzehuang Pharmaceutical Co Ltd Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| CN |
|
Zhangzhou Pientzehuang Pharmaceutical Co Ltd
SSE:600436
|
96.5B CNY | 9.9 | 39.9 | 38.8 | 38.8 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
947.4B USD | 16 | 51.6 | 34.7 | 37.2 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
564B USD | 6 | 21 | 14.6 | 17.9 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
282B CHF | 4.6 | 30 | 12.7 | 14.8 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
214.9B GBP | 5.1 | 31.7 | 15.1 | 22.1 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
290.3B USD | 4.5 | 15.2 | 10.7 | 12.7 | |
| CH |
|
Novartis AG
SIX:NOVN
|
225.6B CHF | 5.2 | 20.2 | 12.7 | 16.4 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.6T DKK | 5.2 | 15.9 | 11 | 12.8 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
218B USD | 94 | -74.6 | 333.1 | 835.4 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
145.7B USD | 2.3 | 14.9 | 7.6 | 10.3 | |
| FR |
|
Sanofi SA
PAR:SAN
|
98B EUR | 1.7 | 8.2 | 7.7 | 7.7 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
